Enoximone

Chemical compound
  • C01CE03 (WHO)
Legal statusLegal status
  • UK: POM (Prescription only)
Pharmacokinetic dataBioavailability50% (oral)Protein binding85%MetabolismLiver (oxidation)Elimination half-life4 to 10 hoursExcretionRenal (60 to 70%)Identifiers
  • 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
CAS Number
  • 77671-31-9 checkY
PubChem CID
  • 53708
DrugBank
  • DB04880 checkY
ChemSpider
  • 48492 checkY
UNII
  • C7Z4ITI7L7
KEGG
  • D04004 checkY
ChEMBL
  • ChEMBL249856 checkY
CompTox Dashboard (EPA)
  • DTXSID8045147 Edit this at Wikidata
Chemical and physical dataFormulaC12H12N2O2SMolar mass248.30 g·mol−13D model (JSmol)
  • Interactive image
Melting point255 to 258 °C (491 to 496 °F) (decomposes)
  • O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
  • InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) checkY
  • Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N checkY
  (verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]

References

  1. ^ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066. S2CID 46021219.

External links

  • Media related to Enoximone at Wikimedia Commons
  • v
  • t
  • e
PDE1PDE2
PDE3PDE4
PDE5PDE7PDE9PDE10
PDE11
BC11-38
Non-selectiveUnsorted
See also: Receptor/signaling modulators


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e